The US Food and Drug Administration approves most drugs based on rigorous randomized clinical trials showing that the drug is “efficacious,” which is operationally defined as statistically superior to placebo. However, a number of critically important knowledge gaps exist long after a drug is approved. For example, many drugs are approved based on studies of a surrogate end point, which is a biological marker or event observable earlier than the clinical end points that are actually of primary interest. For instance, antihypertensive drugs are usually approved on the basis of their ability to reduce blood pressure rather than on their ability to reduce the risk of the clinically important consequences of high blood pressure such as stroke. Unfortunately, reliance on surrogate end points can sometimes produce disastrous results. Encainide hydrochloride and flecainide acetate, 2 antiarrhythmic drugs approved in the early 1980s based on their ability to suppress premature ventricular contractions, which was considered a surrogate end point for reducing cardiac mortality, serve as illustrative examples. Nearly a decade after these drugs were approved, a large randomized trial1 showed that, in direct opposition to expectation, they actually increased mortality in the patient population in whom they were thought to reduce mortality.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
How Should We Treat Patients With Heart Failure? A Problem in Interpreting Study Results
Figure 17.1-1. Distribution of Brain Natriuretic Peptide Values Among Patients With and Without...
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.